Outsourcing

Sep 27, 2007
ePT--the Electronic Newsletter of Pharmaceutical Technology
By Pharmaceutical Technology Editors
Company and People Notes: Evotec and Renovis enter agreement, Amgen to lay off 675 workers, more.
Sep 19, 2007
ePT--the Electronic Newsletter of Pharmaceutical Technology
By Pharmaceutical Technology Editors
Company and People Notes: Catalent expands Bolton, UK, warehouse; Biotica appoints Edward E. Hodgkin as CEO and director; more.
Sep 18, 2007
Pharmaceutical Technology Europe PTE
By Pharmaceutical Technology Editors
Sartorius has officially started up operations at its new plant in Beijing. By building the new facility, the company has now doubled its production capacity in China from approximately 4000 m2 to more than 8000 m2; an additional building phase makes it possible to even quadruple the floor space in the future. The investment volume for the new plant site is about ?10 million.
Sep 13, 2007
ePT--the Electronic Newsletter of Pharmaceutical Technology
By Pharmaceutical Technology Editors
Company and People Notes: Baxter and Halozyme Expand Relationship, Crucell Names COO, More.
Sep 05, 2007
PTSM: Pharmaceutical Technology Sourcing and Management
Aptuit expands its drug-development capabilities with the formation of Aptuit Laurus to take advantage of the growing pharmaceutical outsourcing market in India.
Sep 05, 2007
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Purchase-order contracting is a commonly used approach to conducting commercial transactions, but it is a risky proposition when applied to pharmaceutical transactions, including the buying and selling of contract services and pharmaceutical ingredients. The authors examine the contract provisions covered in a commercial-supply agreement that are likely to be omitted under purchase-order contracting and the risk-reduction benefits that a commercial-supply agreement can offer in pharmaceutical procurement transactions.
Sep 02, 2007
Pharmaceutical Technology
By Pharmaceutical Technology Editors
Useful Contacts
Sep 02, 2007
Pharmaceutical Technology
In a nation of more than 1 billion people, the importance of vaccines goes beyond healthcare—it is a matter of national security. Armed with this belief and a philanthropic vision that most Indians could be protected against hepatitis, DT–Polio, and other afflictions, Dr. Varaprasad Reddy entered the nascent Indian biotechnology sector in 1992 and has since managed to threaten the monopoly of large laboratories. That year, the Hepatitis B vaccine cost $33 per shot, and yet some families were subsisting on less than $1 a day. Meanwhile, India was importing only 180,000 doses per year.
Sep 02, 2007
Pharmaceutical Technology
How the Indian pharmaceutical sector is reinventing itself
Sep 02, 2007
Pharmaceutical Technology
native1_300x100
lorem ipsum